On Thursday, Dynegy Inc. (NYSE:DYN)’s shares enhanced 3.27%, and closed at $31.29, as The Dynegy Inc. (DYN) Board of Directors declared a dividend of $1.34375 per share on the outstanding 5.375% Series A Mandatory Convertible Preferred Stock that will be paid on May 1, 2015 to stockholders of record of the Mandatory Convertible Preferred Stock on April 15, 2015. The dividend is for the dividend period starting on February 1, 2015 and ending on April 30, 2015.
Dynegy Inc., through its auxiliaries, produces and sells electric energy, capacity, and ancillary services in the United States. It operates in three segments, Coal, IPH, and Gas. The corporation sells its services on a wholesale basis from its power generation.
Vale SA (ADR) (NYSE:VALE), inclined 3.23%, and closed at $5.76, hitting new 52-week low of $5.45.
Formerly on March 23, 2015, Investor-Edge has initiated coverage on the following equities: Vale S.A. (VALE), Alcoa Inc. (AA), Freeport-McMoRan Inc. (FCX), Southern Copper Corporation (SCCO), and Century Aluminum Corporation (CENX).
Vale S.A., together with its auxiliaries, engages in the research, production, and sale of iron ore and pellets, nickel, fertilizer, copper, coal, manganese, ferroalloys, cobalt, platinum group metals, and precious metals in Brazil and internationally.
At the end of Thursday’s trade, Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), surged 2.71%, and closed at $0.959, after Lexicon Pharmaceuticals, Inc. (LXRX), declared that it has commenced screening in its first pivotal Phase 3 clinical trial of sotagliflozin for type 1 diabetes.
Lexicon will be conducting two pivotal Phase 3 clinical trials of sotagliflozin, one in North America and another primarily in Europe. Each pivotal trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of sotagliflozin in adult patients with type 1 diabetes. Two dose levels of sotagliflozin, 200mg and 400mg once daily, will be tested together with placebo.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
Lion Biotechnologies Inc (NASDAQ:LBIO), gained 3.11%, and closed at $12.94, as a biotechnology corporation declared that researchers from Moffitt Cancer Center stated positive results from a pilot trial of TIL and ipilimumab in patients with metastatic melanoma. The data from the trial, which Lion partially sponsored, were presented at the Society of Surgical Oncology 2015 meeting in Houston, TX on Friday, March 27, 2015.
The Phase 1 trial was conducted at Moffitt Cancer Center in 12 patients with metastatic melanoma, with the objective of determining the safety and feasibility of combining TIL therapy with the CTLA-4 checkpoint inhibitor, ipilimumab. Patients were treated with ipilimumab one week preceding to tumor harvest for TIL expansion, a second time while their TIL were being expanded, and two more times following TIL transfer.
Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical corporation, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
